Abstract
In the context of regenerative medicine, therapy using autologous cells (in combination with platelet-rich plasma) appears to be a promising option. The so-called medicinal signaling cells (MSC), also known as mesenchymal stem cells, can be obtained, for example, from bone marrow, subcutaneous adipose tissue, or umbilical cord blood, and can be applied to targets of degeneration or inflammation. It is important to adhere to national regulations in this process. In Switzerland, the application of techniques that do not significantly alter or store cells is not subject to transplantation laws and can therefore be used without prior certification as medicinal products. We provide information on the mode of action, indications, and the technique practiced by us.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call